References
- 1. Schrump DS AN, Henschke CL, Carter D, Turris AT, Gutierrez. Cancer: Principle and practice of oncology. Philadelphia: Lippincott William & Wilkins; 2005.
- 2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92-8.10.1056/NEJMoa011954
- 3. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 4285-91.10.1200/JCO.2002.02.068
- 4. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994; 266:807-10.10.1126/science.7973635
- 5. O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57:4285-300.
- 6. Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2003; 39:41-8.10.1016/S0169-5002(02)00391-4
- 7. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998; 34: 1352-7.10.1016/S0959-8049(98)00067-7
- 8. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res. 1997; 3:1195-200.
- 9. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a nonfunctional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002; 97:439-45.10.1002/ijc.1628
- 10. Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000; 45:369-74.10.1007/s002800051004
- 11. Safran H, King T, Choy H, Gollerkeri A, Kwakwa H, Lopez F, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer. 1996; 78:1203-10.10.1002/(SICI)1097-0142(19960915)78:6<1203::AID-CNCR6>3.0.CO;2-A
- 12. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, et al. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer. 2000; 89:769-73.10.1002/1097-0142(20000815)89:4<769::AID-CNCR8>3.0.CO;2-6
- 13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.10.1093/jnci/92.3.205
- 14. Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 2002; 36: 159-65.10.1016/S0169-5002(01)00463-9
- 15. Johnson EA, Klimstra DS, Herndon JE, 2nd, Catalano E, Canellos GP, Graziano SL, et al. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20:686-92.10.1081/CNV-120003537
- 16. Korobowicz E, Zdunek M. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy. Pol J Pathol. 2000; 51:71-6.
- 17. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995; 55:5038-42.
- 18. Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, et al. Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer. 2011; 74:310-7.10.1016/j.lungcan.2011.03.016
- 19. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54:4855-78.
- 20. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005; 10; 331: 834-42.10.1016/j.bbrc.2005.03.190
- 21. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest. 1994; 106(6 Suppl):377S-81S.10.1378/chest.106.6.377S
- 22. Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol. 1999; 162:1496-501.10.1016/S0022-5347(05)68347-4